Literature DB >> 19509545

Molecular genetic analysis of a cell adhesion molecule with homology to L1CAM, contactin 6, and contactin 4 candidate chromosome 3p26pter tumor suppressor genes in ovarian cancer.

Emily N Manderson1, Ashley H Birch, Zhen Shen, Anne-Marie Mes-Masson, Diane Provencher, Patricia N Tonin.   

Abstract

Loss of heterozygosity (LOH) analyses of epithelial ovarian cancers (EOCs) previously identified a candidate tumor suppressor gene (TSG) locus within the chromosomal region 3p25.3-pter. Loss of heterozygosity analysis was performed to define the locus and identify candidates for further study. Loss of heterozygosity analysis of 124 malignant EOC samples of different histopathologic subtypes using 12 polymorphic microsatellite repeat markers identified a 330-kilobase minimal region of overlapping deletions at 3p26.3 that contained contactin 4 (CNTN4) as the only known TSG candidate. However, evaluation of the LOH patterns in the serous EOC samples, the most common subtype, enabled the identification of a second, broader region of LOH also included the cell adhesion molecule with homology to L1CAM (CHL1) and CNTN6 as candidates. Gene expression by reverse transcription polymerase chain reaction was not detectable in primary cultures of normal ovarian surface epithelial cells for any of these candidates. CNTN6 expression was also not detectable in serous EOC samples. In contrast, gene expression of CNTN4 and CHL1, particularly overexpression of CHL1, was observed in serous EOC samples. Mutation and gene expression analyses of well-defined EOC cell lines (OV-90, TOV-112D, TOV-21G, and TOV-81D) that differ in their tumorigenic potential and chromosome 3p26-pter genomic content revealed CNTN4 expression and a novel mutation only in the tumorigenic EOC cell line TOV-21G. This mutation was neither observed in controls (n = 105) nor detected by sequencing analysis of complementary DNA. Taken together, these results do not support the candidacy of CHL1, CNTN6, and CNTN4 as TSGs in the 3p26-pter region. However, the overexpression of CHL1, a member of the L1 cell adhesion molecule (L1CAM) family, warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19509545     DOI: 10.1111/IGC.0b013e3181a3cd38

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  10 in total

Review 1.  Tumor suppressor genes on frequently deleted chromosome 3p in nasopharyngeal carcinoma.

Authors:  Juan Chen; Li Fu; Li-Yi Zhang; Dora L Kwong; Li Yan; Xin-Yuan Guan
Journal:  Chin J Cancer       Date:  2012-02-24

2.  Differential expression of CHL1 gene during development of major human cancers.

Authors:  Vera N Senchenko; George S Krasnov; Alexey A Dmitriev; Anna V Kudryavtseva; Ekaterina A Anedchenko; Eleonora A Braga; Irina V Pronina; Tatiana T Kondratieva; Sergey V Ivanov; Eugene R Zabarovsky; Michael I Lerman
Journal:  PLoS One       Date:  2011-03-07       Impact factor: 3.240

3.  Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours.

Authors:  Ashley H Birch; Suzanna L Arcand; Kathleen K Oros; Kurosh Rahimi; A Kevin Watters; Diane Provencher; Celia M Greenwood; Anne-Marie Mes-Masson; Patricia N Tonin
Journal:  PLoS One       Date:  2011-12-06       Impact factor: 3.240

4.  CHL1 Is Expressed and Functions as a Malignancy Promoter in Glioma Cells.

Authors:  Zhai Yang; Qing Xie; Cheng-Liang Hu; Qiong Jiang; Hui-Fan Shen; Melitta Schachner; Wei-Jiang Zhao
Journal:  Front Mol Neurosci       Date:  2017-10-17       Impact factor: 5.639

5.  Identification of Predictive DNA Methylation Biomarkers for Chemotherapy Response in Colorectal Cancer.

Authors:  Rashidah Baharudin; Nurul-Syakima Ab Mutalib; Sri N Othman; Ismail Sagap; Isa M Rose; Norfilza Mohd Mokhtar; Rahman Jamal
Journal:  Front Pharmacol       Date:  2017-02-13       Impact factor: 5.810

6.  CHL1 gene polymorphisms increase lung cancer susceptibility.

Authors:  Wen Tian; Xuelian Li; Yangwu Ren; Zhihua Yin; Xiaowei Quan; Chang Zheng; Baosen Zhou
Journal:  Oncotarget       Date:  2018-01-06

7.  CHL1 and NrCAM are Primarily Expressed in Low Grade Pediatric Neuroblastoma.

Authors:  Robin Wachowiak; Steffi Mayer; Anne Suttkus; Illya Martynov; Martin Lacher; Nathaniel Melling; Jakob R Izbicki; Michael Tachezy
Journal:  Open Med (Wars)       Date:  2019-12-31

8.  ChIP-seq analysis of histone H3K9 trimethylation in peripheral blood mononuclear cells of membranous nephropathy patients.

Authors:  W G Sui; H Y He; Q Yan; J J Chen; R H Zhang; Y Dai
Journal:  Braz J Med Biol Res       Date:  2013-12-12       Impact factor: 2.590

9.  Candidate genes and pathways downstream of PAX8 involved in ovarian high-grade serous carcinoma.

Authors:  Tiziana de Cristofaro; Tina Di Palma; Amata Amy Soriano; Antonella Monticelli; Ornella Affinito; Sergio Cocozza; Mariastella Zannini
Journal:  Oncotarget       Date:  2016-07-05

10.  CHL1 suppresses tumor growth and metastasis in nasopharyngeal carcinoma by repressing PI3K/AKT signaling pathway via interaction with Integrin β1 and Merlin.

Authors:  Juan Chen; Chen Jiang; Li Fu; Cai-Lei Zhu; Yan-Qun Xiang; Ling-Xi Jiang; Qian Chen; Wai Man Liu; Jin-Na Chen; Li-Yi Zhang; Ming Liu; Chao Chen; Hong Tang; Bo Wang; Sai Wah Tsao; Dora Lai-Wan Kwong; Xin-Yuan Guan
Journal:  Int J Biol Sci       Date:  2019-07-11       Impact factor: 6.580

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.